Targeting the Immune Complex-Bound Complement C3d Ligand as a Novel Therapy for Lupus

Area of Science:

• Immunology
• Rheumatology
• Molecular Biology

Background:

• Humoral autoimmunity is central to systemic lupus erythematosus (SLE) pathogenesis.
• Complement receptor type 2 (CR2)/CD21 is crucial for B cell signaling and immune complex handling.
• Previous studies on CR2's role in murine SLE models yielded contradictory results.

Purpose of the Study:

• To investigate the specific role of the C3d-CR2 interaction in SLE development.
• To evaluate the therapeutic potential of blocking this interaction.

Main Methods:

• Development of a novel, highly specific mouse anti-mouse C3d monoclonal antibody (mAb).
• Utilizing the MRL/lpr mouse model of SLE.
• Assessing the impact of C3d-CR2 blockade on autoimmune and renal disease.

Main Results:

• Disruption of the C3d-CR2 ligand-receptor binding step substantially ameliorated autoimmunity in MRL/lpr mice.
• Renal disease was also significantly improved by blocking the C3d-CR2 interaction.
• This targeted blockade proved effective without genetic deletion of CR2.

Conclusions:

• The C3d-CR2 interaction is a critical driver of autoimmunity and renal pathology in this SLE model.
• Targeting the C3d-CR2 axis represents a promising therapeutic strategy for SLE.
• This approach offers a new avenue for managing SLE by specifically inhibiting a key molecular interaction.